MA30411B1 - Derives de triazolopyrazine utiles comme agent anticancereux - Google Patents

Derives de triazolopyrazine utiles comme agent anticancereux

Info

Publication number
MA30411B1
MA30411B1 MA31378A MA31378A MA30411B1 MA 30411 B1 MA30411 B1 MA 30411B1 MA 31378 A MA31378 A MA 31378A MA 31378 A MA31378 A MA 31378A MA 30411 B1 MA30411 B1 MA 30411B1
Authority
MA
Morocco
Prior art keywords
anticancer agent
derivatives useful
compounds
formula
triazolopyrazine derivatives
Prior art date
Application number
MA31378A
Other languages
English (en)
Inventor
Hengmiao Cheng
Jingrong Jean Cui
Jacqui Elizabeth Hoffman
Lei Jia
Mary Catherine Johnson
Robert Steven Kania
Phuong Thi Quy Le
Mitchell David Nambu
Mason Alan Pairish
Hong Shen
Michelle Bich Tran-Dube
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA30411B1 publication Critical patent/MA30411B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

CETTE INVENTION CONCERNE DES COMPOSÉS DE FORMULE (I) OU UN SEL DE CELLE-CI PHARMACEUTIQUEMENT ACCEPTABLE OÙ R1, R2, R3 ET R4 SONT TELS QUE DÉFINIS DANS LA DESCRIPTION. L'INVENTION CONCERNE ÉGALEMENT LES COMPOSÉS PHARMACEUTIQUES CONTENANT LES COMPOSÉS DE FORMULE I AINSI QUE LES MÉTHODES DE TRAITEMENT DES DÉSORDRES HYPERPROLIFÉRATIFS CHEZ LES MAMMIFÈRES EN ADMINISTRANT DES COMPOSÉS DE FORMULE (I).
MA31378A 2006-05-11 2008-11-11 Derives de triazolopyrazine utiles comme agent anticancereux MA30411B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79996606P 2006-05-11 2006-05-11
US89323107P 2007-03-06 2007-03-06

Publications (1)

Publication Number Publication Date
MA30411B1 true MA30411B1 (fr) 2009-05-04

Family

ID=38441445

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31378A MA30411B1 (fr) 2006-05-11 2008-11-11 Derives de triazolopyrazine utiles comme agent anticancereux

Country Status (32)

Country Link
US (2) US7732604B2 (fr)
EP (1) EP2018383B1 (fr)
JP (1) JP4377962B2 (fr)
KR (1) KR101099161B1 (fr)
CN (1) CN101443331A (fr)
AP (1) AP2008004674A0 (fr)
AR (1) AR060994A1 (fr)
AT (1) ATE532785T1 (fr)
AU (1) AU2007251283A1 (fr)
BR (1) BRPI0711809A2 (fr)
CA (1) CA2651363C (fr)
CR (1) CR10383A (fr)
EA (1) EA016204B1 (fr)
EC (1) ECSP088871A (fr)
ES (1) ES2376913T3 (fr)
GE (1) GEP20115174B (fr)
GT (1) GT200700039A (fr)
HN (1) HN2007015177A (fr)
IL (1) IL194813A0 (fr)
MA (1) MA30411B1 (fr)
ME (1) MEP36508A (fr)
MX (1) MX2008014399A (fr)
NL (1) NL2000613C2 (fr)
NO (1) NO20085060L (fr)
NZ (1) NZ572361A (fr)
PE (1) PE20080067A1 (fr)
RS (1) RS20080533A (fr)
TN (1) TNSN08445A1 (fr)
TW (1) TWI346115B (fr)
UY (1) UY30334A1 (fr)
WO (1) WO2007132308A1 (fr)
ZA (1) ZA200809020B (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8198448B2 (en) * 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
US20110039856A1 (en) * 2007-11-29 2011-02-17 Pfizer Inc. Polymorphs of a c-met/hgfr inhibitor
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
JPWO2009107391A1 (ja) * 2008-02-27 2011-06-30 武田薬品工業株式会社 ６員芳香環含有化合物
PE20091468A1 (es) * 2008-02-28 2009-10-22 Novartis Ag DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA
US8598184B2 (en) * 2008-03-03 2013-12-03 Tiger Pharmatech Protein kinase inhibitors
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
EP2298731A4 (fr) * 2008-06-25 2011-09-21 Takeda Pharmaceutical Composé amide
DE102008037790A1 (de) * 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
EP2356116A1 (fr) * 2008-11-20 2011-08-17 OSI Pharmaceuticals, Inc. Pyrroloý2,3-b¨-pyridines et pyrroloý2,3-b¨-pyrazines substituées
EP2381777A4 (fr) * 2008-12-12 2012-08-08 Ariad Pharma Inc Dérivés d'azaindole en tant qu'inhibiteurs de kinases
EA019320B1 (ru) 2008-12-22 2014-02-28 Мерк Патент Гмбх Новые полиморфные формы дигидрофосфата 6-(1-метил-1h-пиразол-4-ил)-2-{3-[5-(2-морфолин-4-илэтокси)пиримидин-2-ил]бензил}-2h-пиридазин-3-она и способы их получения
WO2010083283A2 (fr) 2009-01-15 2010-07-22 Incyte Corporation Procédés de préparation d'inhibiteurs des jak et composés intermédiaires apparentés
UA106082C2 (uk) * 2009-05-28 2014-07-25 Вертекс Фармасьютікалз Інкорпорейтед АМІНОПІРАЗОЛ ТРИАЗОЛОТІАДІАЗОЛЬНІ ІНГІБІТОРИ ПРОТЕЇНКІНАЗИ c-МЕТ
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt) 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
IN2012DN01453A (fr) * 2009-08-20 2015-06-05 Novartis Ag
DE102009056886A1 (de) 2009-12-03 2011-06-09 Bayer Schering Pharma Aktiengesellschaft cMet-Inhibitoren zur Behandlung der Endometriose
PT3511330T (pt) * 2009-12-31 2020-12-24 Hutchison Medipharma Ltd Intermediário sintético útil na preparação de inibidores de triazolopiridina c-met
TWI423974B (zh) * 2010-02-11 2014-01-21 Hutchison Medipharma Ltd 三氮唑並吡啶和三氮唑並吡嗪化合物及其組合物和應用
US20130072495A1 (en) 2010-05-14 2013-03-21 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
JP5960688B2 (ja) 2010-05-17 2016-08-02 インコゼン セラピューティクス プライベート リミテッド プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物
EP2588107A1 (fr) 2010-07-01 2013-05-08 Takeda Pharmaceutical Company Limited Combinaison d'un inhibiteur de cmet et d'un anticorps dirigé contre hgf et/ou cmet
WO2012042421A1 (fr) 2010-09-29 2012-04-05 Pfizer Inc. Procédé de traitement de la croissance cellulaire anormale
CN102532141A (zh) 2010-12-08 2012-07-04 中国科学院上海药物研究所 [1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途
JP2014513724A (ja) 2011-05-16 2014-06-05 オーエスアイ・ファーマシューティカルズ，エルエルシー 融合二環キナーゼ阻害剤
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
CN102516263B (zh) * 2011-10-25 2015-04-08 南方医科大学 一种螺三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用
CN102503959B (zh) * 2011-10-25 2015-04-08 南方医科大学 一种稠三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用
CN103204844A (zh) * 2012-01-17 2013-07-17 上海艾力斯医药科技有限公司 氨基杂芳基化合物及其制备方法与应用
CN104321322A (zh) 2012-03-30 2015-01-28 理森制药股份公司 作为c-met蛋白激酶调节剂的新型3,5-二取代-3h-咪唑并[4,5-b]吡啶和3,5-二取代-3h-[1,2,3]三唑并[4,5-b]吡啶化合物
MX371119B (es) 2012-04-03 2020-01-17 Novartis Ag Productos de combinacion con los inhibidores de cinasa de tirosina y su uso.
CA2866321A1 (fr) 2012-04-03 2013-10-10 Novartis Ag Combinaisons d'inhibiteurs de tyrosine kinase et leur utilisation
CN105968115B (zh) * 2013-04-17 2018-11-09 上海医药集团股份有限公司 喹啉类化合物、其制备方法、中间体、药物组合物和应用
WO2014174478A1 (fr) 2013-04-26 2014-10-30 Novartis Ag Combinaisons pharmaceutiques d'un inhibiteur de la pkc et d'un inhibiteur du récepteur tyrosine-kinase c-met
AU2013402175B2 (en) * 2013-09-30 2017-09-07 Handok Inc. Novel triazolopyrazine derivative and use thereof
EP3229836B1 (fr) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Anticoprs monoclonaux contre 'axl'
WO2016135041A1 (fr) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Protéines de fusion et anticorps les contenant pour favoriser l'apoptose
JP2018123059A (ja) * 2015-06-10 2018-08-09 石原産業株式会社 １−シクロプロピルエチルアミン又はその塩の製造方法
CR20180109A (es) * 2015-07-20 2018-05-03 Genzyme Corp Inhibidores de receptor del factor estimulador de colonias 1 (csf-1r)
WO2017049711A1 (fr) 2015-09-24 2017-03-30 上海海聚生物科技有限公司 Dérivé de quinoléine, composition pharmaceutique, méthode de préparation et utilisation de celui-ci
ES2877799T3 (es) * 2015-12-31 2021-11-17 Shanghai Pharmaceuticals Holding Co Ltd Sal de derivado de quinolina, formas polimórficas de la misma, métodos de preparación de la misma, composición y aplicaciones
CN120661674A (zh) 2016-03-15 2025-09-19 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
JP7042812B2 (ja) 2016-06-20 2022-03-28 ノバルティス アーゲー トリアゾロピリミジン化合物の結晶形態
KR20180092096A (ko) 2017-02-08 2018-08-17 에이비온 주식회사 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법
CN108570053A (zh) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 五元并六元杂环化合物、制备方法、中间体、组合和应用
CN108276418A (zh) * 2018-03-20 2018-07-13 北京凯恩梅格医药科技有限公司 化合物、含有该化合物的药用组合物及其用途
WO2020124060A1 (fr) 2018-12-14 2020-06-18 Beta Pharma, Inc. Composés substitués par organophosphoré en tant qu'inhibiteurs de c-met et leurs utilisations thérapeutiques
US11530216B2 (en) 2020-12-23 2022-12-20 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (CSF-1R) inhibitors
WO2025098425A1 (fr) * 2023-11-09 2025-05-15 浙江华海药业股份有限公司 Procédé de préparation de modulateur du récepteur de la chimiokine et utilisation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
CA2372813A1 (fr) 1992-02-06 1993-08-19 L.L. Houston Proteine fixatrice biosynthetique pour marqueur du cancer
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
AR007855A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios, uso en medicinay composiciones farmaceuticas que los contienen
US6391874B1 (en) 1996-07-13 2002-05-21 Smithkline Beecham Corporation Fused heterocyclic compounds as protein tyrosine kinase inhibitors
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
KR20020088406A (ko) * 1999-09-17 2002-11-27 애보트 게엠베하 운트 콤파니 카게 치료제로서의 피라졸로피리미딘
JP2007516180A (ja) * 2003-07-02 2007-06-21 スゲン，インコーポレイティド ｃ−Ｍｅｔ阻害薬としてのアリールメチルトリアゾロおよびイミダゾピラジン類
AU2004274403A1 (en) 2003-09-03 2005-03-31 Aventis Pharmaceuticals Inc. 5-aryl-Pyrazolo(4,3-d)pyrimidines, pyridines, and pyrazines and related compounds
US10181126B2 (en) 2012-03-13 2019-01-15 American Express Travel Related Services Company, Inc. Systems and methods for tailoring marketing
US10884952B2 (en) 2016-09-30 2021-01-05 Intel Corporation Enforcing memory operand types using protection keys

Also Published As

Publication number Publication date
CR10383A (es) 2008-11-11
US20100105656A1 (en) 2010-04-29
TW200804384A (en) 2008-01-16
AP2008004674A0 (en) 2008-12-31
CA2651363A1 (fr) 2007-11-22
US7732604B2 (en) 2010-06-08
ATE532785T1 (de) 2011-11-15
EA200870423A1 (ru) 2009-04-28
CN101443331A (zh) 2009-05-27
ES2376913T3 (es) 2012-03-20
KR101099161B1 (ko) 2011-12-27
EA016204B1 (ru) 2012-03-30
US20070265272A1 (en) 2007-11-15
EP2018383B1 (fr) 2011-11-09
RS20080533A (sr) 2009-09-08
AU2007251283A1 (en) 2007-11-22
GEP20115174B (en) 2011-03-10
TWI346115B (en) 2011-08-01
IL194813A0 (en) 2009-08-03
WO2007132308A1 (fr) 2007-11-22
UY30334A1 (es) 2008-01-02
NZ572361A (en) 2012-02-24
BRPI0711809A2 (pt) 2011-12-06
MEP36508A (en) 2011-02-10
AR060994A1 (es) 2008-07-30
ZA200809020B (en) 2009-12-30
JP4377962B2 (ja) 2009-12-02
NO20085060L (no) 2008-12-03
PE20080067A1 (es) 2008-03-10
JP2009536636A (ja) 2009-10-15
GT200700039A (es) 2008-06-02
TNSN08445A1 (fr) 2010-04-14
MX2008014399A (es) 2008-11-27
KR20090006187A (ko) 2009-01-14
EP2018383A1 (fr) 2009-01-28
ECSP088871A (es) 2008-12-30
HN2007015177A (es) 2010-06-09
NL2000613C2 (nl) 2007-11-20
CA2651363C (fr) 2011-07-12

Similar Documents

Publication Publication Date Title
TNSN08445A1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
MA30403B1 (fr) Derives d'acides cycloalkylamines et leurs compositions pharmaceutiques
MA31373B1 (fr) Composes amino-heterocycliques
MA27568A1 (fr) Derives de pyrrolopyrimidine
TNSN04246A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
TN2010000175A1 (fr) Piperidino-dihydrothienopyrimidines substituees
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
TN2009000138A1 (fr) Biaryl-ether-urees
MA30089B1 (fr) (arylsulfonyl)-pyrasolopiperidines
MA43639B1 (fr) Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA33734B1 (fr) N1-pyrazolospirocétone inhibitrices d'acétyl-coa carboxylase
MA31766B1 (fr) Composés organiques
MA30991B1 (fr) Utilisation de dérivés du benzamide comme agonistes des récepteurs ep4
MA27775A1 (fr) Composes organiques
MA29926B1 (fr) Derives de pyrazine
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
MA27769A1 (fr) Dérivées de 2-acylamino-4-phenylthiazole, leur préparation et leur application en thérapeutique
TN2009000544A1 (fr) Derives de benzimidazole
MA30694B1 (fr) Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
MA32108B1 (fr) Derives d'indazole
MA29213B1 (fr) Quinolones a substitution macrolones - amino
MA34308B1 (fr) Triazolopyridines substituées
MA30821B1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2